These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38852812)

  • 61. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
    Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
    J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
    Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
    Jung M; Song SG; Cho SI; Shin S; Lee T; Jung W; Lee H; Park J; Song S; Park G; Song H; Park S; Lee J; Kang M; Park J; Pereira S; Yoo D; Chung K; Ali SM; Kim SW
    Breast Cancer Res; 2024 Feb; 26(1):31. PubMed ID: 38395930
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
    Gordian-Arroyo AM; Zynger DL; Tozbikian GH
    Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
    Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
    JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
    Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
    Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues.
    Qaiser T; Mukherjee A; Reddy Pb C; Munugoti SD; Tallam V; Pitkäaho T; Lehtimäki T; Naughton T; Berseth M; Pedraza A; Mukundan R; Smith M; Bhalerao A; Rodner E; Simon M; Denzler J; Huang CH; Bueno G; Snead D; Ellis IO; Ilyas M; Rajpoot N
    Histopathology; 2018 Jan; 72(2):227-238. PubMed ID: 28771788
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
    Gough M; Liu C; Srinivasan B; Wilkinson L; Dunk L; Yang Y; Schreiber V; Tuffaha H; Kryza T; Hooper JD; Lakhani SR; Snell CE
    Histopathology; 2023 Oct; 83(4):647-656. PubMed ID: 37366040
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
    Bardia A; Viale G
    Target Oncol; 2023 May; 18(3):313-319. PubMed ID: 37133651
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
    Lloyd MC; Allam-Nandyala P; Purohit CN; Burke N; Coppola D; Bui MM
    J Pathol Inform; 2010 Dec; 1():29. PubMed ID: 21221174
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HER2 expression in urothelial carcinoma, a systematic literature review.
    Scherrer E; Kang A; Bloudek LM; Koshkin VS
    Front Oncol; 2022; 12():1011885. PubMed ID: 36338710
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A testing algorithm for determination of HER2 status in patients with breast cancer.
    Nichols DW; Wolff DJ; Self S; Metcalf JS; Jacobs D; Kneuper-Hall R; Cate JC
    Ann Clin Lab Sci; 2002; 32(1):3-11. PubMed ID: 11848614
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
    Fernandez AI; Liu M; Bellizzi A; Brock J; Fadare O; Hanley K; Harigopal M; Jorns JM; Kuba MG; Ly A; Podoll M; Rabe K; Sanders MA; Singh K; Snir OL; Soong TR; Wei S; Wen H; Wong S; Yoon E; Pusztai L; Reisenbichler E; Rimm DL
    JAMA Oncol; 2022 Apr; 8(4):1-4. PubMed ID: 35113160
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines.
    Vergara-Lluri ME; Moatamed NA; Hong E; Apple SK
    Mod Pathol; 2012 Oct; 25(10):1326-32. PubMed ID: 22699517
    [TBL] [Abstract][Full Text] [Related]  

  • 80. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF;
    Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.